WO2002069927A1 - Preparations de melatonine-vitamine-a - Google Patents

Preparations de melatonine-vitamine-a Download PDF

Info

Publication number
WO2002069927A1
WO2002069927A1 PCT/EP2002/002355 EP0202355W WO02069927A1 WO 2002069927 A1 WO2002069927 A1 WO 2002069927A1 EP 0202355 W EP0202355 W EP 0202355W WO 02069927 A1 WO02069927 A1 WO 02069927A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
composition according
melatonin
acid
derivative
Prior art date
Application number
PCT/EP2002/002355
Other languages
German (de)
English (en)
Inventor
Hans W. Schmid
Original Assignee
Asat Ag Applied Science & Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asat Ag Applied Science & Technology filed Critical Asat Ag Applied Science & Technology
Publication of WO2002069927A1 publication Critical patent/WO2002069927A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition which contains a combination of melatonin and vitamin A as active ingredients.
  • the composition is particularly suitable for the production of formulations for topical use on the skin and in the hair.
  • vitamin A in particular in the form of vitamin A acid
  • side effects include dermal irritation, which can cause reddening of the skin to various degrees. With sensitive skin, even edema or blisters can occur.
  • sunscreens After using a vitamin A preparation, exposure to sunlight or UV radiation should also be avoided. It is therefore strongly recommended to use sunscreens with a protection factor of 1 5 or more.
  • the present invention thus relates to a composition which comprises as active ingredients (a) melatonin or a derivative thereof and (b) vitamin A or a derivative thereof, in particular vitamin A acid or a derivative thereof.
  • the composition is preferred a topical formulation suitable for pharmaceutical or cosmetic applications.
  • the composition according to the invention contains a combination of active ingredients.
  • the first component of this combination is melatonin or a melatonin derivative, wherein melatonin derivatives are preferably selected from 5-methoxytryptamine, 5-M ethoxytryptophan, 5-methoxytryptophol, 5-methoxyindole-3-acetic acid and 6-hydroxymelatonin.
  • physiologically acceptable salts, esters and complex compounds thereof can also be used.
  • the second component of the composition is vitamin A or a vitamin A derivative, in particular selected from vitamin A acetate and vitamin A palmitate and in particular vitamin A acid (retinoic acid) or a derivative thereof, such as an ester, Salt or a complex compound of retinoic acid.
  • vitamin A acid retinoic acid
  • Physiologically acceptable salts, esters and complex compounds are preferably used.
  • composition according to the invention can contain the active ingredients dissolved or / and dispersed in a liquid, semi-solid or solid carrier system.
  • suitable carrier systems are liquids such as water, physiologically acceptable organic solvents such as ethanol or combinations thereof, oil-water emulsions, water-oil emulsions, fats, polyethylene glycols, propylene glycols, glycerol, emulsifiers or combinations thereof, and others in pharmaceutical and cosmetic formulations Carriers or auxiliaries used.
  • compositions can be obtained which allow a controlled release of at least one of the active ingredients, in particular of both active ingredients.
  • concentration of the active ingredients in the composition - depending on the application - can be varied within a wide range. Conveniently, the concentrations of the active ingredients are each independently in the range between 0.001% (weight) to 1% (weight) based on the total weight of the composition.
  • compositions according to the invention are particularly suitable for pharmaceutical or / and cosmetic applications, for example on the skin and / or in the hair.
  • the transdermal absorption of at least one of the active ingredients is preferably controllable.
  • compositions can be in the form of a solution, suspension, emulsion, microemulsion, nanosystem, cream, gel, lotion, spray, foam or ointment or in any other form suitable for topical applications. They are usually used in a packaging or application system selected from tubes, bottles, spray bottles, plasters, sponges and textile or plastic carriers and other systems suitable for application to the skin and / or in the hair.
  • the combination preparations according to the invention are particularly recommended for use in the evening and are particularly effective during the night.
  • the reduction in the side effects of vitamin A acid caused by melatonin is particularly strong.
  • compositions according to the invention are suitable for reducing or preventing the side effects of vitamin A, vitamin A acid or their derivatives due to the addition of melatonin. Furthermore, an increase in the physiological effect, in particular the wrinkle-reducing effect of vitamin A is found due to the addition of melatonin.
  • Vitamin A acid and melatonin were integrated in concentrations of 0.001% to 1% (wt.) In stable pharmaceutically and cosmetically applicable liposomal carriers to control the delivery of effects.
  • the Bangha et al. (Dermatology 1 95 (1 997), 248-252) described nanocarriers were used to produce the combination preparations according to the invention in order to achieve a targeted release of the active ingredient.
  • solid carrier systems such as agarose in various particle sizes, which contain vitamin A acid and melatonin distributed in the carrier system, have been successfully used for targeted drug delivery.
  • Combination preparations of vitamin A acid and melatonin have also been produced and successfully applied in emulsions, such as the Retin A formulation by Ortho Dermatological.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition contenant, comme principes actifs, une association de mélatonine et de vitamine A ou d'acide de vitamine A. Cette composition est adaptée notamment à la production de formulations destinées à une utilisation topique sur la peau et les cheveux.
PCT/EP2002/002355 2001-03-05 2002-03-04 Preparations de melatonine-vitamine-a WO2002069927A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2001110418 DE10110418A1 (de) 2001-03-05 2001-03-05 Melatonin-Vitamin-A-Präparate
DE10110418.9 2001-03-05

Publications (1)

Publication Number Publication Date
WO2002069927A1 true WO2002069927A1 (fr) 2002-09-12

Family

ID=7676289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002355 WO2002069927A1 (fr) 2001-03-05 2002-03-04 Preparations de melatonine-vitamine-a

Country Status (2)

Country Link
DE (1) DE10110418A1 (fr)
WO (1) WO2002069927A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024361A1 (fr) * 2007-08-22 2009-02-26 Henkel Ag & Co. Kgaa Agents de traitement capillaire contenant un ou plusieurs alcools et de la mélatonine/agomélatine
WO2009024359A1 (fr) * 2007-08-22 2009-02-26 Henkel Ag & Co. Kgaa Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine
US8017645B2 (en) 2002-10-30 2011-09-13 Asat Ag Applied Science & Technology Melatonin daily dosage units
KR101675062B1 (ko) 2016-03-24 2016-11-11 김삼 멜라토닌을 이용한 이중 코팅된 순수 비타민 c 및 이를 함유하는 화장료 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294909C (zh) * 2004-03-19 2007-01-17 谭敦宁 一种新型抗生物细胞自由基氧化损伤合剂
ITRM20060108A1 (it) 2006-03-03 2007-09-04 Colella Gino Composizioni a base di melatonina e sostanze immunostimolanti
CN103608006B (zh) 2011-04-01 2017-07-07 伊亚索梅股份公司 包含n‑乙酰基‑l‑半胱氨酸的组合及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617477A1 (de) * 1967-06-22 1970-01-08 Fischer Geb Beutelschiess Alwi Biologisches Haarwuchs-Tonicum mit Garantie
FR2741802A1 (fr) * 1995-12-04 1997-06-06 Oreal Utilisation de melatonine pour traiter les peaux sensibles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617477A1 (de) * 1967-06-22 1970-01-08 Fischer Geb Beutelschiess Alwi Biologisches Haarwuchs-Tonicum mit Garantie
FR2741802A1 (fr) * 1995-12-04 1997-06-06 Oreal Utilisation de melatonine pour traiter les peaux sensibles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE PROMT [online] GALE GROUP.; "Sweet Dreams Melatonin Night Cream", XP002203288, retrieved from STN Database accession no. 97:288562 *
HISTORY OF SHEA BUTTER, 2002, XP002203287, Retrieved from the Internet <URL:http://www.organicsheabutter.com/history.htlm> [retrieved on 20020624] *
LE MAGAZINE, January 2000 (2000-01-01), XP002203286, Retrieved from the Internet <URL:http://www.lef.org/magazine/mag2000/jan00-products.html> [retrieved on 20020624] *
PRODUCT ALTERT, 12 May 1997 (1997-05-12) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017645B2 (en) 2002-10-30 2011-09-13 Asat Ag Applied Science & Technology Melatonin daily dosage units
US8062648B2 (en) 2002-10-30 2011-11-22 Asat Ag Applied Science & Technology Formulations containing melatonin, ginkgo biloba, and biotin
WO2009024361A1 (fr) * 2007-08-22 2009-02-26 Henkel Ag & Co. Kgaa Agents de traitement capillaire contenant un ou plusieurs alcools et de la mélatonine/agomélatine
WO2009024359A1 (fr) * 2007-08-22 2009-02-26 Henkel Ag & Co. Kgaa Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine
KR101675062B1 (ko) 2016-03-24 2016-11-11 김삼 멜라토닌을 이용한 이중 코팅된 순수 비타민 c 및 이를 함유하는 화장료 조성물

Also Published As

Publication number Publication date
DE10110418A1 (de) 2002-09-12

Similar Documents

Publication Publication Date Title
JP2855105B2 (ja) 化粧品用組成物
DE69720978T2 (de) Topische mittel, die eine öl-in-wasser emulsion und ein retinoid enthalten
EP0633017B1 (fr) Compositions cosmétiques et dermatologiques contenant de l&#39;acide delta-aminolevulinique
DE69427639T3 (de) Verwendung von nicht-ionischen oberflächenaktiven substanzen in retinoid enthaltenden stabilen topischen zusammensetzungen
DE4420625C1 (de) Wirkstoffkombination mit einem Gehalt an Glycerylalkylethern und kosmetische und dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
US5002760A (en) Retinol skin care composition
EP1308169A1 (fr) Composition-réservoir pour admistration topique de composées peu solubles dans l&#39;eau, leur préparation et usage
DE3402880C2 (fr)
WO1994025069A1 (fr) Preparation transdermique de principes actifs
DD298352A5 (de) Tretinoin enthaltende zubereitung und verfahren zu ihrer herstellung
DE4305788C2 (de) Kosmetische und dermatologische Formulierungen zum Schutze der Haut gegen Oxidationsprozesse
DE602004012440T2 (de) Sprühbare zusammensetzung zur verabreichung von vitamin d derivaten
EP1569724B1 (fr) Formulations contenant de la melatonine, du ginkgo biloba et de la biotine
DE4431251C2 (de) Hautcreme
EP0509338A1 (fr) Fabrication et utilisation de préparations stables de liposomes de petite taille
DE602005003138T3 (de) Zusammensetzung in sprayform mit einer kombination aus clobetasolpropionat und calcitriol, einer alkoholphase und ölphase
DE2601489C2 (fr)
DE60019086T2 (de) Zusammensetzungen zur behandlung von hautkrankheiten
DE10155200A1 (de) Verwendung von Cholesterin, cholesterinhaltigen Substanzen oder von den Cholesteringehalt erhöhenden Substanzen in kosmetischen und dermatologischen Zubereitungen zum Zwecke der UV-Protektion
WO2002069927A1 (fr) Preparations de melatonine-vitamine-a
DE60304478T2 (de) Topische zusammensetzung enthaltend ketoprofen stabilisiert mit sulisobenzon
WO1996008517A1 (fr) Esters d&#39;acides gras et de dextrane solubles dans l&#39;eau et leur utilisation comme agents solubilisants
DE69402259T2 (de) Zusammensetzungen enthaltend 8-Hydroxychinolin zur Behandlung hyperproliferativer Hautkrankheiten
EP1885328A1 (fr) Combinaisons de matieres actives formees de glycerides de glucosyle et de creatine et/ou de creatinine
DE69700042T2 (de) Stabile gelierte Zusammensetzung, die gegenüber Sauerstoff und/oder Wasser empfindliche lipophile Wirkstoffe enthält

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP